{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:14:52Z","timestamp":1789953292671,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1208\/s12248-018-0219-4","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T15:12:49Z","timestamp":1523977969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF\u03b1 Monoclonal Antibody"],"prefix":"10.1208","volume":"20","author":[{"given":"Weirong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"issue":"6","key":"219_CR1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"219_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","volume":"33","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679\u20130.","journal-title":"Clin Ther"},{"issue":"9","key":"219_CR3","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552\u201363.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"219_CR4","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","volume":"71","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914\u20135.","journal-title":"Ann Rheum Dis"},{"key":"219_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA Schouwenburg Van","year":"2013","unstructured":"Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:164\u201372.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"219_CR6","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"P Emery","year":"2009","unstructured":"Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor \u03b1 monoclonal antibody, injected subcutaneously every four weeks in methotrexate-na\u00efve patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272\u201383.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"219_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J. 2012 Jun;14(2):296\u2013302.","journal-title":"AAPS J"},{"key":"219_CR8","doi-asserted-by":"publisher","first-page":"2342187","DOI":"10.1155\/2016\/2342187","volume":"2016","author":"A Smith","year":"2016","unstructured":"Smith A, Manoli H, Jaw S, Frutoz K, Epstein AL, Khawli LA, et al. Unraveling the effect of immunogenicity on the PK\/PD, efficacy, and safety of therapeutic proteins. J Immunol Res. 2016;2016:2342187.","journal-title":"J Immunol Res"},{"key":"219_CR9","first-page":"1","volume":"21","author":"H Zhou","year":"2016","unstructured":"Zhou H, Sharma A. Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies. Expert Opin Drug Metab Toxicol. 2016;21:1\u20139.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"219_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1124\/jpet.104.079277","volume":"313","author":"JR Rojas","year":"2005","unstructured":"Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. JPET. 2005;313(2):578\u201385.","journal-title":"JPET"},{"issue":"1","key":"219_CR11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0090-9556(24)14878-7","volume":"27","author":"WF Richter","year":"1999","unstructured":"Richter WF, Gallati H, Schiller CD. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. DMD. 1999;27(1):21\u20135.","journal-title":"DMD"},{"issue":"21","key":"219_CR12","doi-asserted-by":"publisher","first-page":"13481","DOI":"10.1073\/pnas.172501499","volume":"99","author":"PT Rajagopalan","year":"2002","unstructured":"Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc Natl Acad Sci U S A. 2002;99(21):13481\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"219_CR13","doi-asserted-by":"crossref","unstructured":"Wijngaarden S, van Roon JAG, van de Winkel JGJ, Bijlsma JWJ, Lafeber FPJG. Down-regulation of activating Fc\u03b3 receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment Rheumatology. 2005;44: 729\u201334.","DOI":"10.1093\/rheumatology\/keh583"},{"key":"219_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4161\/mabs.12304","volume":"2","author":"DJ Shealy","year":"2010","unstructured":"Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor \u03b1. MAbs. 2010;2:428\u201339.","journal-title":"MAbs"},{"key":"219_CR15","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64:2504\u201317.","journal-title":"Arthritis Rheum"},{"key":"219_CR16","first-page":"147","volume-title":"ADME and translational pharmacokinetics\/pharmacodynamics of therapeutic proteins-applications in drug discovery and development","author":"H Kropshofer","year":"2015","unstructured":"Kropshofer H, Richter WF. Immunogenicity: its impact on ADME of therapeutic biologics. In: Zhou H, Thiel FP, editors. ADME and translational pharmacokinetics\/pharmacodynamics of therapeutic proteins-applications in drug discovery and development. Hoboken: Wiley; 2015. p. 147\u201358."},{"issue":"5","key":"219_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.4161\/mabs.25234","volume":"5","author":"PJ Meer Van","year":"2013","unstructured":"Van Meer PJ, Kooijman M, Brinks V, Gispen-de Wied CC, Silva-Lima B, Moors EH, et al. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs. 2013;5(5):810\u20136.","journal-title":"MAbs"},{"issue":"7","key":"219_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2174\/138920009789895499","volume":"10","author":"JH Lin","year":"2009","unstructured":"Lin JH. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab. 2009 Sep;10(7):661\u201391.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"219_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1208\/s12248-012-9353-6","volume":"14","author":"T Prueksaritanont","year":"2012","unstructured":"Prueksaritanont T, Tang C. ADME of biologics-what have we learned from small molecules? AAPS J. 2012;14(3):410\u20139.","journal-title":"AAPS J"},{"issue":"2","key":"219_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/19420862.2015.1115937","volume":"8","author":"J Tibbitts","year":"2016","unstructured":"Tibbitts J, Canter D, Graff R, Smith A, Khawli LA. Key factors influencing ADME properties of therapeutic proteins: a need for ADME characterization in drug discovery and development. MAbs. 2016;8(2):229\u201345.","journal-title":"MAbs"},{"issue":"16","key":"219_CR21","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.300.16.1887","volume":"300","author":"TJ Glezen","year":"2008","unstructured":"Glezen TJ, Mantel-Teeuwisse AK, Straus S, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300(16):1887\u201396.","journal-title":"JAMA"},{"issue":"4","key":"219_CR22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1208\/s12248-013-9495-1","volume":"15","author":"J Kenny","year":"2013","unstructured":"Kenny J, Liu M, Chow AT, Earp JC, Evers R, Slatter G, et al. Therapeutic protein drug\u2013drug interactions: navigating the knowledge gaps\u2014highlights from the 2012 AAPS NBC roundtable and IQ consortium\/FDA workshop. AAPS J. 2013;15(4):933\u201340.","journal-title":"AAPS J"},{"key":"219_CR23","first-page":"1","volume-title":"Drug-drug interactions for therapeutic biologics","author":"H Zhou","year":"2013","unstructured":"Zhou H, Meibohm B. Drug interactions for therapeutic proteins: a journey just beginning. In: Zhou H, Meibohm B, editors. Drug-drug interactions for therapeutic biologics. Hoboken: Wiley; 2013. p. 1\u20134."},{"key":"219_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/clpt.2009.308","volume":"87","author":"S-M Huang","year":"2010","unstructured":"Huang S-M, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, et al. Therapeutic protein\u2013drug interactions and implications for drug development. Clin Pharmacol Ther. 2010;87:497\u2013503.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"219_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1208\/s12248-011-9285-6","volume":"13","author":"S Girish","year":"2011","unstructured":"Girish S, Martin SW, Peterson MC, Zhang LK, Zhao H, Balthasar J, et al. AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development. AAPS J. 2011;13(3):405\u201316.","journal-title":"AAPS J"},{"issue":"10","key":"219_CR26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1124\/dmd.111.040808","volume":"39","author":"E Kraynov","year":"2011","unstructured":"Kraynov E, Martin SW, Hurst S, Fahmi OA, Dowty M, Cronenberger C, et al. How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential. Drug Metab Dispos. 2011;39(10):1779\u201383.","journal-title":"Drug Metab Dispos"},{"issue":"8 Pt 2","key":"219_CR27","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/clinchem\/42.8.1322","volume":"42","author":"SP Treon","year":"1996","unstructured":"Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996;42(8 Pt 2):1322\u20139.","journal-title":"Clin Chem"},{"issue":"2","key":"219_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1208\/s12248-016-0026-8","volume":"19","author":"J Herskovitz","year":"2017","unstructured":"Herskovitz J, Ryman J, Thway T, Lee S, Zhou L, Chirmule N, et al. Immune suppression during preclinical drug development mitigates immunogenicity-mediated impact on therapeutic exposure. AAPS J. 2017;19(2):447\u201355.","journal-title":"AAPS J"},{"issue":"3","key":"219_CR29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1208\/s12248-013-9484-4","volume":"15","author":"TM Thway","year":"2013","unstructured":"Thway TM, Magana I, Bautista A, Jawa V, Gu W, Ma M. Impact of anti-drug antibodies in preclinical pharmacokinetic assessment. AAPS J. 2013;15(3):856\u201363.","journal-title":"AAPS J"},{"issue":"3","key":"219_CR30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1208\/s12248-014-9582-y","volume":"16","author":"JM Sailstad","year":"2014","unstructured":"Sailstad JM, Amaravadi L, Clements-Egan A, Gorovits B, Myler HA, Pillutla RC, et al. A white paper\u2014consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J. 2014;16(3):488\u201398.","journal-title":"AAPS J"},{"issue":"1","key":"219_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clinthera.2011.11.015","volume":"34","author":"Y Zhuang","year":"2012","unstructured":"Zhuang Y, Xu Z, Frederick B, de Vries DE, Ford JA, Keen M, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther. 2012;34(1):77\u201390.","journal-title":"Clin Ther"},{"key":"219_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2125.2011.04050.x","volume":"73","author":"D Ternant","year":"2012","unstructured":"Ternant D, Mulleman D, Lauferon F, Vignault C, Ducourau E, Wendling D, et al. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol. 2012;73:55\u201365.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"219_CR33","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/ar3350","volume":"13","author":"D Mulleman","year":"2011","unstructured":"Mulleman D, Lauf\u00e9ron F, Wendling D, Ternant D, Ducourau E, Paintaud G, et al. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther. 2011;13(3):R82.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"219_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","volume":"53","author":"M Jani","year":"2014","unstructured":"Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213\u201322.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"219_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13063-017-1777-y","volume":"18","author":"CI Busard","year":"2017","unstructured":"Busard CI, Menting SP, van Bezooijen JS, van den Reek JM, Hutten BA, Prens EP, et al. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. Trials. 2017;18(1):52.","journal-title":"Trials"},{"issue":"2","key":"219_CR36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jpba.2010.08.022","volume":"54","author":"J Li","year":"2011","unstructured":"Li J, Schantz A, Schwegler M, Shankar G. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet\u00ae biolayer interferometry. J Pharm Biomed Anal. 2011;54(2):286\u201394.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"219_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1365-2249.2002.01777.x","volume":"128","author":"G Strauss","year":"2002","unstructured":"Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128(2):255\u201366.","journal-title":"Clin Exp Immunol"},{"key":"219_CR38","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4161\/mabs.1.6.10185","volume":"1","author":"Z An","year":"2009","unstructured":"An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, et al. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs. 2009;1:572\u20139.","journal-title":"MAbs"},{"key":"219_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/s10165-009-0158-0","volume":"19","author":"S Nishio","year":"2009","unstructured":"Nishio S, Yamamoto T, Kaneko K, Tanaka-Matsumoto N, Muraoka S, Kaburaki M, et al. Pharmacokinetic study and Fcgamma receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab. Mod Rheumatol. 2009;19:329\u201333.","journal-title":"Mod Rheumatol"},{"issue":"1\u20132","key":"219_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijpharm.2012.09.042","volume":"439","author":"L Abuqayyas","year":"2012","unstructured":"Abuqayyas L, Balthasar JP. Application of knockout mouse models to investigate the influence of Fc\u03b3R on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. Int J Pharm. 2012;439(1\u20132):8\u201316.","journal-title":"Int J Pharm"},{"issue":"10","key":"219_CR41","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/rheumatology\/keg323","volume":"42","author":"AH Gerards","year":"2003","unstructured":"Gerards AH, de Lathouder S, de Groot ER, Dijkmans BAC, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology. 2003;42(10):1189\u201396.","journal-title":"Rheumatology"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-018-0219-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-018-0219-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-018-0219-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T18:50:21Z","timestamp":1751568621000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-018-0219-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1208\/s12248-018-0219-4","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"13 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Animal Care and Use Committee (IACUC) of WuXi AppTec.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}],"article-number":"63"}}